Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00081809
Other study ID # C-100-09
Secondary ID MDACC Protocol I
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2000
Est. completion date June 2005

Study information

Verified date September 2023
Source Agenus Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objectives: - To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma. The efficacy endpoints are: - the rate of complete and partial responses - the time to progression. Secondary Objectives: - To evaluate the safety and tolerability of autologous tumor-derived heat-shock protein peptide complex (HSPPC-96) administered intradermally once weekly for four consecutive weeks, followed by HSPPC-96 administered once every two weeks. - To evaluate the feasibility of autologous HSPPC-96 preparation from lymphoma specimens. - To assess approximately the composition of the tissue source of the autologous HSPPC-96 for each patient. - To study the effect of autologous lymphoma-derived HSPPC-96 vaccine therapy on the expression of Fas ligand and TRAIL death proteins in peripheral blood lymphocytes of patients with indolent lymphoma.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date June 2005
Est. primary completion date June 2005
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients with previously treated or newly diagnosed follicular center cell grade I or grade II lymphoma, small lymphocytic lymphoma, MALT lymphoma, monocytoid B-cell lymphoma, Waldenstrom's macroglobulinemia, or marginal zone lymphoma with bidimensionally measurable disease; - Part of the resected specimen must undergo routine pathologic examination to confirm the diagnosis of lymphoma. The remaining tissue must be used for the preparation of autologous HSPPC-96; - Autologous HSPPC-96 vaccine must be successfully prepared and provided by the sponsor; - A minimum of 2 grams of non-necrotic, resectable malignant lymphoma for HSPPC-96 preparation; - Bidimensionally measurable disease in at least one location other than the resected lymphoid tissue; - Life expectancy of at least 16 weeks; - Zubrod performance status of less then or equal to 2; - Adequate bone marrow function; - Adequate hepatic function; - Adequate renal function; - Signed written informed consent; - Patients of child-bearing potential must practice contraception, which is adequate in the opinion of the Principal Investigator; - Patients of child-bearing potential must have a negative serum pregnancy test prior to entry into the study and must not be lactating; - Patients must be willing to be followed at the M. D. Anderson Cancer Center during the course of treatment and follow-up; - Electrocardiogram if none performed in the prior six months; - Patients must have no chemotherapy, immunotherapy, radiotherapy, or experimental anti-cancer therapy within six weeks prior to starting autologous HSPPC-96 administration; - Patients must have fully recovered from prior anti-cancer therapy; - Tumor measurements and staging no more than 4 weeks prior to receiving the first dose of autologous HSPPC-96. Exclusion Criteria: - Patients with active or prior history of central nervous system lymphoma; - Patients with serious intercurrent medical illnesses, requiring hospitalization; - Patients with a history of primary or secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on functional immune system) or patients taking immunosuppressive drugs such as systemic corticosteroids; - Women who are pregnant or lactating; - Patients participating in another clinical trial; - Patients receiving growth factors of any kind, including G-CSF, GM-CSF, or Epogen; - Patients with bulky disease, defined as greater than 10 cm in diameter; - Patients with positive HIV antibody; - Patients with more than 4 previous treatment regimens will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
autologous human tumor-derived HSPPC-96


Locations

Country Name City State
United States M.D. Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Agenus Inc.

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT01950273 - Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma Phase 1
Completed NCT00930514 - A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma Phase 1
Completed NCT02472756 - Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma N/A
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00193492 - A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Phase 2
Withdrawn NCT00092274 - Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma Phase 1/Phase 2
Completed NCT03087929 - Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon N/A
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT00915096 - Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
Recruiting NCT05849857 - Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries Phase 2
Recruiting NCT05410418 - Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma Phase 2
Terminated NCT01609036 - An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma N/A
Completed NCT01234766 - Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Terminated NCT00384111 - Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) Phase 3
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Active, not recruiting NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Phase 1
Terminated NCT00562965 - Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Active, not recruiting NCT00317096 - FCM Versus R-FCM Followed by R-Maintenance or Observation Only Phase 3